Eli Lilly executive on crucial tirzepatide data: "It is a very exciting time"

Before the turn of the year, Eli Lilly will receive the phase III results for the drug tirzepatide, meant to beat the best products in the top-selling GLP-1 segment on the diabetes market. Jamie Croaning, who leads the development of the drug at Eli Lilly, speaks of a paradigm shift.

The US pharmaceutical company Eli Lilly is Novo Nordisk's greatest competitor on the diabetes market.

Before New Year's, the bar will be raised for how well a diabetes drug can perform when Eli Lilly displays the first phase III results from the future hope tirzepatide.

That is, at least, the hope that Eli Lilly's Global Brand Development Leader James Croaning has. He is in charge of the development of tirzepatide in Eli Lilly's diabetes business.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs